SCHEMBL5750801

SCHEMBL5750801

COc1ccc2cc(C(O)c3ccncc3)ccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.51
AKR1C3 P42330 6/20 0.50
AKR1C2 P52895 6/20 0.50
PTGS2 P35354 3/20 0.50
PTGS1 P23219 3/20 0.50
TSHR P16473 2/20 0.50
CDC42 P60953 1/20 0.50
RAC1 P63000 1/20 0.50
CYP1A2 P05177 1/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP11B1 P15538 2/20 0.47
CYP11B2 P19099 2/20 0.47
CYP17A1 P05093 3/20 0.47
AKR1C1 Q04828 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
RIOK2 Q9BVS4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23882638 0.86 CYP17A1 (0.57) TSHRCYP1A2LMNACYP2C9CYP11B1
SCHEMBL23882639 0.86 CYP17A1 (0.57) TSHRCYP1A2LMNACYP2C9CYP11B1
SCHEMBL3284398 0.83 AKR1C3 (0.57) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL28512510 0.82 ABCB11 (0.53) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL23882848 0.82 ROCK1 (0.50) CYP2C9L3MBTL1CYP3A4
SCHEMBL23882846 0.82 ROCK1 (0.50) CYP2C9L3MBTL1CYP3A4
SCHEMBL5752462 0.82 CYP11B2 (0.55) ABCB11CYP1A2CYP2C9CYP11B1CYP11B2
SCHEMBL28519052 0.81 MEN1 (0.51) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL4828425 0.80 AKR1C3 (0.54) ABCB11AKR1C3AKR1C2PTGS2PTGS1
SCHEMBL7812703 0.80 ABCB11 (0.58) ABCB11AKR1C3AKR1C2PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084149-B2 Naphthalene derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-08-01 US disclosed
EP-1073640-B1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL (JP) 2005-04-13 EP disclosed
US-20030236274-A1 Naphthalene derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-25 US disclosed
US-6573289-B1 Naphthalene derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-06-03 US disclosed
EP-1073640-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2001-02-07 EP disclosed
WO-1999054309-A1 NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236274-A1 Naphthalene derivatives, their production and use CYP17A1, CYP21A2, HSD17B1 ABCB11 738/4885AKR1C3 42/4885AKR1C2 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.